Presentations & Webinars

Investor Presentation

May 2, 2019

2019 TCT Late Breaking Oral Presentation of Phase 3 SIERRA Trial of Iomab-B

Feb 25, 2019

Iomab-B Phase 3 Oral Presentation at ASH 2018

Dec 5, 2018

CD33 Program Update – Actimab-A Post Phase 2 Results and Actimab-MDS Regulatory Update

Oct 26, 2018

Company Update - Next Generation Lymphodepletion Technology for CAR-T Conditioning

Sep 26, 2018

Iomab-B DMC Update Conference Call

Aug 15, 2018

Actimab-A MRD clinical trial for Minimal Residual Disease in Postremission AML Patients Webcast

Jul 10, 2018

CD33 Program Expansion: Actimab-A + CLAG-M Conference Call

Feb 13, 2018

AACR 2019 Actimab-A Venetoclax in vivo Combination Results

Apr 2, 2019

ASH 2017 Actimab-A Preliminary Phase 2 Results

Dec 14, 2017

• 1
• 2
• Next »